Evidence map›Paper›PMID 37205500›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Evaluation of the Performance of the RECODe Equation with the Addition of Polygenic Risk Scores for Adverse Cardiovascular Outcomes in Individuals with Type II Diabetes.

Noah L Tsao, Renae Judy, Michael G Levin, Gabrielle Shakt, Regeneron Genetics Center, Penn Medicine BioBank, Benjamin F Voight, Jinbo Chen, Scott M Damrauer

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Noah L TsaoCorporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.
Renae JudyCorporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.
Michael G LevinCorporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.
Gabrielle ShaktCorporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.
Regeneron Genetics Center
Penn Medicine BioBank
Benjamin F VoightCorporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.
Jinbo ChenDepartment of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Scott M DamrauerCorporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA.
Philadelphia VA Medical Center · USCardiovascular Institute of the South · USTranslational Therapeutics (United States) · US

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Functional Interrogation of T2D-associated genes in human stem cell-derived models and miceUM1DK126194 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GRANT, STRUAN F A, KAESTNER, KLAUS H · 2020 to 2024
$8.8M
Data and Information Integration for Risk Prediction in the Era of Big DataR01CA236468 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHEN, JINBO · 2019 to 2024
$2.2M
Statistical Methods for Analyzing Electronic Health Record DataR01HL138306 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHEN, JINBO · 2018 to 2020
$1.2M
CSRD VA IK2 CX001780NCATS NIH HHS UL1 TR001878NCI NIH HHS R01 CA236468NHLBI NIH HHS R01 HL138306NIDDK NIH HHS UM1 DK126194
6 · The paper itself

Abstract

Aims/Hypothesis: Individuals with T2D are at an increased risk of developing cardiovascular complications; early identification of individuals can lead to an alteration of the natural history of the disease. Current approaches to risk prediction tailored to individuals with T2D are exemplified by the RECODe algorithms which predict CVD outcomes among individuals with T2D. Recent efforts to improve CVD risk prediction among the general population have included the incorporation of polygenic risk scores (PRS). This paper aims to investigate the utility of the addition of a coronary artery disease (CAD), stroke and heart failure risk score to the current RECODe model for disease stratification. Methods: We derived PRS using summary statistics for ischemic stroke (IS) from the coronary artery disease (CAD) and heart failure (HF) and tested prediction accuracy in the Penn Medicine Biobank (PMBB). A Cox proportional hazards model was used for time-to-event analyses within our cohort, and we compared model discrimination for the RECODe model with and without a PRS using AUC. Results: The RECODe model alone demonstrated an AUC [95% CI] of 0.67 [0.62-0.72] for ASCVD; the addition of the three PRS to the model demonstrated an AUC [95% CI] of 0.66 [0.63-0.70]. A z-test to compare the AUCs of the two models did not demonstrate a detectable difference between the two models (p=0.97). Conclusions/Interpretation: In the present study, we demonstrate that although PRS associate with CVD outcomes independent of traditional risk factors among individuals with T2D, the addition of PRS to contemporary clinical risk models does not specifically improve the predictive performance as compared to the baseline model.

Identifiers

PMID37205500
PMCPMC10187440
OpenAlexW4372349933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.